Company profile

GRAIL

GRAIL has raised $3.22B across rounds including $300M Series C (May 2018), $390M Series D (Nov 2019), and a $325M post-IPO transaction (Oct 2025) per supplied data. Founded in 2016, GRAIL developed the Galleri multi-cancer early detection blood test using ultra-deep sequencing of cell-free DNA and machine learning. Funding supported large clinical trials, technology scale-up, and regulatory engagement to bring population-scale cancer screening closer to clinical practice. GRAIL aims to enable earlier cancer detection across multiple types to improve patient outcomes.

Back to profiles

Quick facts

Total funding: $3.22B
Founded: 2016

Reach buyers like GRAIL on TexAu

TexAu helps go-to-market teams find, enrich, and reach companies that match this profile. Pick the path that fits how you work.

Find companies like GRAIL
Build a list by industry, headcount, funding stage, or technographics. Get verified emails and direct dials.
Start a free workspace
Enrich your CRM with company data
Push funding, headcount, hiring signals, and tech stack into HubSpot, Salesforce, or a spreadsheet. Waterfall enrichment.
See how the waterfall works
Run it on a schedule
Refresh the list weekly, score new accounts as they land, and push the ones that fit to Smartlead, Instantly, Lemlist, HeyReach, or Apollo Sequences.
See how schedulers work

Reach buyers like GRAIL.

The 14-day trial ships every feature, no card required.

Start free →